



# R.G.C.C. - RESEARCH GENETIC CANCER CENTRE S.A.

Florina, \_\_/\_\_/\_\_\_\_

Dear Colleague,

We send you the results from the analysis on a patient Mr.Ms.\_\_\_\_\_ suffering from \_\_\_\_\_ carcinoma stage \_\_\_\_\_. The sample that was sent to us for analysis was a sample of \_\_\_ml of whole blood that contained EDTA-Ca as anti-coagulant, and packed with an ice pack.

In our laboratory we made the following:

- We isolated the malignant cells using Oncoquick with a membrane that isolates malignant cells from normal cells after centrifugation and positive and negative selection using multiple cell markers.

The results during the isolation procedure are presented below:

**Table of markers:**

CD45 positive cells (Hematologic origin cells)		CD45 negative cells (non Hematologic origin)	
CD15	NEGATIVE	CD34	NEGATIVE
CD30	NEGATIVE	CD99	NEGATIVE
BCR-ABL	NEGATIVE	EpCam	POSITIVE
CD34	NEGATIVE	VHL mut	Dim POSITIVE
CD19	NEGATIVE	CD133	POSITIVE
		CD44	NEGATIVE
		Nanog	POSITIVE
		OKT-4	Dim POSITIVE
		Sox-2	POSITIVE
		PSMA	NEGATIVE
		c-MET	POSITIVE
		CD31	NEGATIVE
		CD19	NEGATIVE
		MUC-1	NEGATIVE
		CD63	NEGATIVE
		panCK	Dim POSITIVE

**Index of marker:** CD45:Hematologic origin cell marker, BCR-ABL, CD30: hematologic malignancy marker, CD133, Sox-2, OKT-4, Nanog, CD44: tumor stem cell marker, CD15: hematological malignancy marker, CD19 (CD45 negative cells – Non Hematologic origin cells): hematological malignancy, CD19 (CD45 positive cells – Hematologic origin cells): lung neuroendocrine malignancy, CD31: endothelial cell membrane antigen, CD34: hematological stem cell and blast cell marker, epithelioid sarcoma marker, CD63: melanoma cell marker, CD99: sarcoma marker, EpCam: epithelial origin marker, MUC-1: Breast cancer antigen, PSMA: prostate specific cancer stem cell membrane antigen, VHL mut: renal carcinoma marker, c-MET: membrane antigen that regulates the mesenchymal to epithelial transition, panCK: epithelial origin cell marker.

**The final results after the isolation procedure are presented below:** We notice that after isolation procedure there are remaining malignant cells. The concentration of these cells was isolated \_\_\_cells/ml, SD +/- 0.3cells.

Sincerely,

Ioannis Papatotiriou M.D., PhD  
Head of molecular medicine dpt of  
R.G.C.C.-RESEARCH GENETIC CANCER CENTRE S.A.

**Index of circulating cells number:** (If Over limit: Advanced or Progression of Disease, If Less than limit: Early disease or disease is responding to a treatment plan).

Breast cancer: < 5cells /7.5ml , Prostate cancer < 20cells/ml , Sarcoma: <15cells/6.5ml, Colon cancer: <5cells/ml, Lung cancer (Lc=0, r=0.99): <10cell/ml. All cancer types other than those listed above should be <5 cells/ml.

\*This test will NOT DETECT cancers of the brain or other cancers that have been "encapsulated" by the body, not releasing circulating tumor or stem cells (CTC, CSC) into the blood stream or if any of these cells are dormant. We still recommend the use of biopsy, blood markers and/or various scans with this test when cancer is suspected or known to exist.No test is 100% accurate.

Mr./Ms.\_\_\_\_\_

Industrial Area of Florina, GR 53100 – Florina, Greece  
Tel.: +30 23850 41950, 41951, 41960, 41961, Fax.: +30 23850 41931  
Website: [www.rgcc-group.com](http://www.rgcc-group.com) E-mail: [papatotiriou.ioannis@rgcc-genlab.com](mailto:papatotiriou.ioannis@rgcc-genlab.com)

Day, \_\_/\_\_/\_\_\_\_